Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Candel Therapeutics (CADL) Equity Ratio (2020 - 2025)

Candel Therapeutics' Equity Ratio history spans 4 years, with the latest figure at 0.31 for Q4 2023.

  • On a quarterly basis, Equity Ratio fell 49.63% to 0.31 in Q4 2023 year-over-year; TTM through Dec 2023 was 0.31, a 49.63% decrease, with the full-year FY2023 number at 0.31, down 49.63% from a year prior.
  • Equity Ratio hit 0.31 in Q4 2023 for Candel Therapeutics, down from 0.46 in the prior quarter.
  • Over the last five years, Equity Ratio for CADL hit a ceiling of 0.72 in Q4 2021 and a floor of 1.4 in Q2 2021.
  • Historically, Equity Ratio has averaged 0.31 across 4 years, with a median of 0.6 in 2023.
  • Biggest five-year swings in Equity Ratio: surged 216.82% in 2021 and later plummeted 49.63% in 2023.
  • Tracing CADL's Equity Ratio over 4 years: stood at 0.62 in 2020, then surged by 216.82% to 0.72 in 2021, then fell by 14.58% to 0.61 in 2022, then tumbled by 49.63% to 0.31 in 2023.
  • Business Quant data shows Equity Ratio for CADL at 0.31 in Q4 2023, 0.46 in Q3 2023, and 0.52 in Q2 2023.